Nova Scotia Becomes Sixth Jurisdiction To Implement Biosimilar Switching
Policy Welcomed By Trade And Advocacy Groups
Executive Summary
Citizens enrolled on Nova Scotia’s Pharmacare programs have 12 months to switch to biosimilar versions of certain biologic drugs, including some insulins and medications used to treat Crohn’s disease and rheumatoid arthritis.
You may also be interested in...
Biosimilars ‘Policy Salad’ Setting Back Sector, Canadian Study Says
The Ontario Drug Policy Research Network has released a new study on biosimilar uptake across Canada, where the use of biosimilars is relatively low in comparison to other OECD countries.
Biosimilars ‘Policy Salad’ Setting Back Sector, Canadian Study Says
The Ontario Drug Policy Research Network has released a new study on biosimilar uptake across Canada, where the use of biosimilars is relatively low in comparison to other OECD countries.
What’s Next? Five Things To Look Out For In May
This month, Eli Lilly’s Alimta blockbuster will lose patent protection in the US, while Teva – which will also publish its Q1 financial results – will see Bristol Myers Squibb begin its appeal process against a key UK ruling involving the originator’s Eliquis (apixaban) anticoagulant.